Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ovid Therapeutics (OVID) Total Current Liabilities (2020 - 2025)

Historic Total Current Liabilities for Ovid Therapeutics (OVID) over the last 6 years, with Q3 2025 value amounting to $6.8 million.

  • Ovid Therapeutics' Total Current Liabilities fell 4156.49% to $6.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $6.8 million, marking a year-over-year decrease of 4156.49%. This contributed to the annual value of $10.5 million for FY2024, which is 828.9% down from last year.
  • According to the latest figures from Q3 2025, Ovid Therapeutics' Total Current Liabilities is $6.8 million, which was down 4156.49% from $8.9 million recorded in Q2 2025.
  • Over the past 5 years, Ovid Therapeutics' Total Current Liabilities peaked at $16.3 million during Q1 2021, and registered a low of $6.7 million during Q1 2023.
  • For the 5-year period, Ovid Therapeutics' Total Current Liabilities averaged around $10.4 million, with its median value being $10.1 million (2021).
  • As far as peak fluctuations go, Ovid Therapeutics' Total Current Liabilities plummeted by 5275.46% in 2022, and later surged by 6409.87% in 2023.
  • Quarter analysis of 5 years shows Ovid Therapeutics' Total Current Liabilities stood at $14.8 million in 2021, then crashed by 52.75% to $7.0 million in 2022, then soared by 64.1% to $11.5 million in 2023, then decreased by 8.29% to $10.5 million in 2024, then crashed by 35.41% to $6.8 million in 2025.
  • Its Total Current Liabilities was $6.8 million in Q3 2025, compared to $8.9 million in Q2 2025 and $9.3 million in Q1 2025.